1. In Vivo
  2. >>Leadership

Drug Delivery Outsourcing In A World Of Pharma’s Shifting Sands

 
• By Jo Shorthouse

The contract drug delivery industry is facing disruptive influences from an evolving client base, the increase in biologics manufacturing and specialty pharma needs. In Vivo speaks to Catalent’s vice president of strategy, Cornell Stamoran, about the evolution of the industry and the continuous search for efficiency.

IV1809_Catalent_1200.jpg
• Source: Shutterstock

The contract drug delivery market has evolved in line with several different factors: financing, client base, and product innovation. Once a vibrant sub-set of the outsourced offerings to the biopharmaceutical industry, three public companies dominated the space: RP Scherer Corp., Elan Corp. PLC and Alza Corp.

However, as the sector evolved, divergent strategies of the three largest companies changed the face of the contract drug delivery ecosystem, and by 2001 it was unrecognizable from the industry it had been just five years previously. Elan became a speciality pharmaceutical company when it bought Athena Neurosciences Inc. in 1995, RP Scherer was acquired by Cardinal Health Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from C-Suite Speaks

More from Leadership